Harnessing AI and Real-World Evidence to Advance Alzheimer’s Screening and Equitable Access
Explore how AI-driven real-world data reveals trends in Alzheimer’s screening, testing, and treatment—and highlights where inequities persist.
Entries by Jalene Kaiser
Leading Medical Affairs Through Transformation: Applying Goleman’s Six Styles with Emotional Intelligence
This session will explore Part 2 of our 3-part MAPS series turns insight into action. In Part 1, we unpacked Daniel Goleman’s five elements of Emotional Intelligence (EI). Now we put EI to work.
The Role of Medical Affairs/Medical Safety in Medical Device Post-Market Risk Assessment & Management
Guide and templates for Medical Affairs input into MedTech Health Hazard Assessment
2025 Medical Affairs Launch Readiness and Execution Benchmark Report
The Medical Affairs Professional Society (MAPS) is pleased to share the 2025 Medical Affairs Launch Readiness and Execution Benchmark Report. This report is based on findings from 28 leading organizations across Pharmaceutical, Biotech, and Medical and Diagnostic Device sectors, and reflects broad leadership thinking about the role of Medical in product launch, current and future challenges, and the capabilities required to succeed in the future.
Unlocking Externally Sponsored Research Value
EvGen strategies via CSS are stretched, prompting companies to use ESR more strategically, including for registration and signal-seeking.
Redefining Evidence Generation: Innovative AI-Enabled Approaches for a New Era of Therapies
This webinar will explore how new approaches are transforming evidence generation for registries and studies by leveraging structured and unstructured electronic health records, creating flexible, living platforms that adapt as new standards of care and questions emerge.
Medical Affairs In Early Stage Development? Seriously?
Join our experts who will be covering the burning platform that is early stage drug development, listen and ask them questions on their thoughts on the role of Medical Affairs in early-stage drug development.